Researchers at the NCI have developed chimeric antigen receptors (CARs) with a high affinity for mesothelin to be used as an immunotherapy to treat pancreatic cancer, ovarian cancer, and mesothelioma. Cells that express CARs, most notably T cells, are highly reactive against their specific tumor antigen in an MHC-unrestricted manner to generate an immune response that promotes robust tumor cell elimination when infused into cancer patients.
This licensing opportunity from the National Cancer Institute concerns the development of CARs comprising an antigen-binding fragment derived from the MGA271 antibody. The resulting CARs can be used in adoptive cell therapy treatment for neuroblastoma and other tumors that express CD276.
Researchers at the National Institute on Aging (NIA) have discovered novel microparticles that are formed using a coacervation process; the biodegradable microbead or microparticle is useful for the sustained localized delivery of biologically active proteins or other molecules of pharmaceutical interest. The microparticles have a matrix structure comprised of the reaction product of at least one cationic polymer, at least one anionic polymer, and a binding component (e.g. gelatin, chondroitin sulfate, avidin).
NCI researchers developed a combination therapy of histone deacetylase (HDAC) inhibitors and immunotherapies, such as checkpoint inhibitors, virus-based vaccines, monoclonal antibodies, cell-based treatments or radiopharmaceuticals. The NCI Laboratory of Tumor Immunology and Biology seeks parties to license or co-develop this method.
Investigators at the National Cancer Institute (NCI) seek co-development partners and/or licensees for a new therapeutic approach that selectively targets cancer cells and prevents tumor regrowth. The novel method combines antibody-IR700 molecules and Near-Infrared Photo Immunotherapy (NIR-PIT), which has shown great potential in targeting tumors via a host immunogenic response, with already known and available anti-cancer immunomodulators to further enhance the antitumor response. The investigators have shown in mouse models that, when used in combination, NIR-PIT-treatment and standard antitumor agents conferred a potent vaccine-like effect, not only curing mice of local and distant cancers but successfully immunizing them against tumor regrowth.
Researchers at the National Cancer Institute developed a novel method of immunogenic modulation in androgen and endocrine deprivation therapy. A combination of hormone therapy with immunotherapies such as PROSTVAC™, a Brachyury vaccine, PROVENGE™, ipilumimab, nivolumab, XOFIGO™, PANVAC, a yeast-MUC-1 immunotherapeutic, or HERCEPTIN™ can benefit prostate and breast cancer patients, especially those who have acquired resistances. The researchers seek parties to co-develop this method.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks licenses and/or co-development partners for methods of treating cancer by administering PIKFYVE inhibitors and P38 MAP kinase inhibitors.
NCI researchers have identified novel compounds that inhibit FKBP52-mediated activation of the androgen receptor protein (AR), a major target for anti-prostate cancer therapeutic development. As FKBP52 is implicated in the regulation of other hormone receptors, anti-FKBP52 may be applicable in the treatment of hormone-dependent diseases such as diabetes or even used as contraceptives. NCI seeks partners to license or co-develop this technology.
Scientists at the National Cancer Institute (NCI) developed a novel stealth lipid-based nanoparticle formulation comprising phospholipid, DC8,9PC and a polyethylene glycol-ated (PEGylated) lipid – such as DSPE-PEG2000 – that efficiently package a high amounts of hydrophobic photodynamic drug (PDT) – such as HPPH – in stable vesicles. This HPPH-loaded liposome system demonstrates higher serum stability and ambient temperature stability upon storage. It exhibits increased tumor accumulation and improved animal survival in mice tumor models compared to the formulation in current clinical trials. The NCI seeks co-development partners and/or corporate licensees for the application of the technology as an anti-cancer therapeutic.
Scientists at the National Institute on Drug Abuse (NIDA) have developed novel dopamine D3 receptor (D3R) agonists with high affinity and selectivity. Two lead compounds, 53 and eutomer 53a, have demonstrated significantly higher D3R binding selectivity than reference compounds. Moreover, 53 and 53a showed metabolic stability in liver microsomes, which is favorable for the future use of these compounds as therapeutic agents for diseases related to dopamine system dysregulation such as Parkinson’s Disease and Restless Legs Syndrome. Researchers at NIDA seek licensing and/or co-development research collaborations for the use of these D3R agonists as molecular tools for the study of D3R physiology and as potential therapeutics to treat neurological and neuropsychiatric disorders.
Investigators at the NCI discovered an Anti-TNF Induced Apoptosis (ATIA) protein, which protects cells against apoptosis. ATIA is highly expressed in glioblastoma and astrocytomas and its inhibition results in increased cell sensitivity to TNF-related apoptosis-inducing ligand induced cell death. The National Cancer Institute seeks parties interested in licensing or collaborative research to further develop, evaluate, or commercialize glioblastoma diagnostics and therapeutics.
Researchers at the National Cancer Institute (NCI) developed cell free methods for efficiently producing high titer, papillomavirus virus-based gene transfer vectors. These vectors can potentially be used for vaccines and/or cancer therapeutic applications. NCI seeks licensing and/or co-development research collaborations for further development of these vectors.
Multi-potential hematopoietic progenitor cells (HPC) can differentiate into any class of blood cells, and are highly useful in regenerative medicine, immunology, and cancer immunotherapy. Current methods to generate HPCs are limited either due to the use of animal products, or the high cost and low efficiency of animal product free systems. Researchers at the National Cancer Institute (NCI) have developed a protocol to prepare HPCs from human induced pluripotent stem cells (hiPSC), using human mesenchymal stem cells (hMSC) in a three-dimensional (3D) co-culture condition. Thus, they are able to generate HPCs in a fully human, autologous system, which can be used to further generate immune cells for therapy. This protocol is adaptable to mass production by bioreactors. NCI seeks licensees for these methods of generating HPCs in a 3D co-culture with hMSCs to be used in a variety of applications such as treatment of blood disorders, regenerative medicine, and antibody production.
Researchers at the National Cancer Institute (NCI) have isolated seven monoclonal antibodies that bind to the human epidermal growth factor receptor variant III (EGFRvIII) but not wildtype EGFR. The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.
Regulatory B-cells (Breg) play an important role in reducing autoimmunity and reduced levels of these cells are implicated in etiology of several auto-inflammatory diseases. Despite their impact in many diseases, their physiological inducers are unknown. The National Eye Institute seeks parties interested in licensing or collaborative research to co-develop a process for the production of regulatory B-Cells for use in auto-immune indications.
Researchers at the National Cancer Institute (NCI) have developed a novel method for identifying neoantigen reactive T cells and T cell receptors (TCRs), isolated from fresh tumors of common epithelial cancers. This highly specific and sensitive method allows rapid determination of the neoantigen reactive TCR sequences and can be very useful to translate this information into TCR-engineered T-cell populations for immunotherapy without the need to grow tumor infiltrating T-cells and expensive, time-consuming screening. The NCI seeks research co-development partners and/or licensees for this invention.